Canada's Med BioGene Files for US IPO; Plans to Launch RT qPCR-based Lung Cancer Test This Year

Med BioGene said that it will use the proceeds from the IPO to complete the validation of its first test, called LungExpress Dx, on a real-time, quantitative reverse transcriptase PCR platform. The test was initially developed on the Affymetrix GeneChip platform.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.